Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.12
LZAGY's Cash to Debt is ranked higher than
56% of the 258 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.79 vs. LZAGY: 0.12 )
LZAGY' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.12

Equity to Asset 0.33
LZAGY's Equity to Asset is ranked higher than
56% of the 240 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. LZAGY: 0.33 )
LZAGY' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.5
Current: 0.33

0.3
0.5
F-Score: 5
Z-Score: 1.88
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.78
LZAGY's Operating margin (%) is ranked higher than
80% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. LZAGY: 9.78 )
LZAGY' s 10-Year Operating margin (%) Range
Min: 7.06   Max: 15.02
Current: 9.78

7.06
15.02
Net-margin (%) 5.11
LZAGY's Net-margin (%) is ranked higher than
82% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. LZAGY: 5.11 )
LZAGY' s 10-Year Net-margin (%) Range
Min: 2.43   Max: 14.27
Current: 5.11

2.43
14.27
ROE (%) 8.79
LZAGY's ROE (%) is ranked higher than
81% of the 232 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. LZAGY: 8.79 )
LZAGY' s 10-Year ROE (%) Range
Min: 4.12   Max: 23.3
Current: 8.79

4.12
23.3
ROA (%) 2.77
LZAGY's ROA (%) is ranked higher than
79% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. LZAGY: 2.77 )
LZAGY' s 10-Year ROA (%) Range
Min: 1.28   Max: 8.48
Current: 2.77

1.28
8.48
ROC (Joel Greenblatt) (%) 7.58
LZAGY's ROC (Joel Greenblatt) (%) is ranked higher than
75% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. LZAGY: 7.58 )
LZAGY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 7.76   Max: 46.01
Current: 7.58

7.76
46.01
Revenue Growth (%) 10.50
LZAGY's Revenue Growth (%) is ranked higher than
83% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. LZAGY: 10.50 )
LZAGY' s 10-Year Revenue Growth (%) Range
Min: -5.5   Max: 12.8
Current: 10.5

-5.5
12.8
EBITDA Growth (%) -4.60
LZAGY's EBITDA Growth (%) is ranked higher than
65% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. LZAGY: -4.60 )
LZAGY' s 10-Year EBITDA Growth (%) Range
Min: -12.2   Max: 36.1
Current: -4.6

-12.2
36.1
EPS Growth (%) -32.90
LZAGY's EPS Growth (%) is ranked higher than
59% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. LZAGY: -32.90 )
LZAGY' s 10-Year EPS Growth (%) Range
Min: -32.9   Max: 29.6
Current: -32.9

-32.9
29.6
» LZAGY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with LZAGY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 65.00
LZAGY's P/E(ttm) is ranked higher than
79% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LZAGY: 65.00 )
LZAGY' s 10-Year P/E(ttm) Range
Min: 8.61   Max: 69.7
Current: 65

8.61
69.7
P/B 2.70
LZAGY's P/B is ranked higher than
79% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.37 vs. LZAGY: 2.70 )
LZAGY' s 10-Year P/B Range
Min: 0.74   Max: 4.1
Current: 2.7

0.74
4.1
P/S 1.60
LZAGY's P/S is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.06 vs. LZAGY: 1.60 )
LZAGY' s 10-Year P/S Range
Min: 0.63   Max: 2.58
Current: 1.6

0.63
2.58
PFCF 18.20
LZAGY's PFCF is ranked higher than
93% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LZAGY: 18.20 )
LZAGY' s 10-Year PFCF Range
Min: 6.16   Max: 21.28
Current: 18.2

6.16
21.28
EV-to-EBIT 30.80
LZAGY's EV-to-EBIT is ranked higher than
78% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LZAGY: 30.80 )
LZAGY' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 32.6
Current: 30.8

9.1
32.6
PEG 72.44
LZAGY's PEG is ranked higher than
78% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LZAGY: 72.44 )
LZAGY' s 10-Year PEG Range
Min: 0.31   Max: 77.44
Current: 72.44

0.31
77.44
Shiller P/E 24.60
LZAGY's Shiller P/E is ranked higher than
94% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LZAGY: 24.60 )
LZAGY' s 10-Year Shiller P/E Range
Min: 6.24   Max: 26.39
Current: 24.6

6.24
26.39
Current Ratio 1.57
LZAGY's Current Ratio is ranked higher than
59% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. LZAGY: 1.57 )
LZAGY' s 10-Year Current Ratio Range
Min: 1.23   Max: 1.99
Current: 1.57

1.23
1.99
Quick Ratio 0.92
LZAGY's Quick Ratio is ranked higher than
53% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. LZAGY: 0.92 )
LZAGY' s 10-Year Quick Ratio Range
Min: 0.73   Max: 1.18
Current: 0.92

0.73
1.18

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.90
LZAGY's Dividend Yield is ranked higher than
81% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.31 vs. LZAGY: 1.90 )
LZAGY' s 10-Year Dividend Yield Range
Min: 0.96   Max: 6.38
Current: 1.9

0.96
6.38
Dividend Payout 0.54
LZAGY's Dividend Payout is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LZAGY: 0.54 )
LZAGY' s 10-Year Dividend Payout Range
Min: 0.22   Max: 1.29
Current: 0.54

0.22
1.29
Dividend growth (3y) 7.10
LZAGY's Dividend growth (3y) is ranked higher than
78% of the 50 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.10 vs. LZAGY: 7.10 )
LZAGY' s 10-Year Dividend growth (3y) Range
Min: 4.9   Max: 10.4
Current: 7.1

4.9
10.4
Yield on cost (5-Year) 2.59
LZAGY's Yield on cost (5-Year) is ranked higher than
73% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. LZAGY: 2.59 )
LZAGY' s 10-Year Yield on cost (5-Year) Range
Min: 1.31   Max: 8.7
Current: 2.59

1.31
8.7
Share Buyback Rate 0.30
LZAGY's Share Buyback Rate is ranked higher than
90% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.60 vs. LZAGY: 0.30 )
LZAGY' s 10-Year Share Buyback Rate Range
Min: 0.6   Max: -3.4
Current: 0.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 18.90
LZAGY's Price/Tangible Book is ranked higher than
63% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.74 vs. LZAGY: 18.90 )
LZAGY' s 10-Year Price/Tangible Book Range
Min: 2.27   Max: 15.87
Current: 18.9

2.27
15.87
Price/DCF (Projected) 2.10
LZAGY's Price/DCF (Projected) is ranked higher than
86% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LZAGY: 2.10 )
LZAGY' s 10-Year Price/DCF (Projected) Range
Min: 1.56   Max: 5.8
Current: 2.1

1.56
5.8
Price/Median PS Value 1.00
LZAGY's Price/Median PS Value is ranked higher than
77% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.32 vs. LZAGY: 1.00 )
LZAGY' s 10-Year Price/Median PS Value Range
Min: 0.45   Max: 1.58
Current: 1

0.45
1.58
Price/Graham Number 7.10
LZAGY's Price/Graham Number is ranked higher than
82% of the 281 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LZAGY: 7.10 )
LZAGY' s 10-Year Price/Graham Number Range
Min: 1.17   Max: 5.97
Current: 7.1

1.17
5.97
Earnings Yield (Greenblatt) 3.20
LZAGY's Earnings Yield (Greenblatt) is ranked higher than
77% of the 253 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. LZAGY: 3.20 )
LZAGY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 11
Current: 3.2

3.1
11
Forward Rate of Return (Yacktman) 3.58
LZAGY's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.35 vs. LZAGY: 3.58 )
LZAGY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -4.3   Max: 31.1
Current: 3.58

-4.3
31.1

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:O6Z.Singapore, 0QNO.UK, LONN.Switzerland, LO3.Germany,
Lonza Group AG was founded in 1897. The Company is a suppliers of biopharmaceuticals to the Pharma&Biotech and Specialty Ingredient markets. Its products and services range from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens, from the manufacture of vitamin B compounds and organic personal care ingredients to agricultural services and products. The Company operates in two market segments: The Lonza Pharma&Biotech and The Lonza Specialty Ingredients. The Lonza Pharma&Biotech (LPB) market segment clusters all of its offerings for pharmaceutical markets, with strong Lonza positions in Custom Development, Custom Manufacturing and Bioscience Solutions. The Lonza Specialty Ingredients (LSI) market segment includes consumer-oriented offerings, with Consumer Care encompassing its Personal Care & Preservation, Nutrition and Hygiene offerings.
» More Articles for LZAGY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Lonza and AdAlta Announce a Strain Development Contract for Novel Biologic Therapeutics Dec 18 2014
Lonza Executes Collaboration Agreements with Two Innovation Clusters Dec 10 2014
MemreePlus™ Studies Provide Evidence of Benefit to Memory, Mood and Cognitive Function in Elderly Dec 02 2014
Lonza Consumer Care to Commence Distribution Relationship with KODA Care Nov 13 2014
Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for... Nov 03 2014
Lonza’s Overall Business Performance Year-to-Date on Track Oct 31 2014
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement Oct 30 2014
Guidance for Enterovirus D68 (EV-D68) Control by the CDC Oct 29 2014
Guidance for Environmental Infection Control for Ebola Virus Oct 22 2014
Lonza Completes Successful Implementation of Next-Generation Carniking Process Mar 27 2014
Lonza Publishes Annual Report 2013 and Invitation to the Annual General Meeting 2014 Mar 20 2014
Lonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with arGEN-X Mar 19 2014
Board of Directors Proposes Barbara Richmond and Juergen Steinemann as New Board Members – Peter... Mar 04 2014
Lonza Offers Lonzagard® Disinfectants for Flu Virus Infection Prevention and Control Feb 25 2014
Lonza Signs Exclusive Agreement with Index Ventures for the Development and Manufacture of Biologics... Jan 28 2014
Lonza Extends Partnership with Pharmacyclics to Support Manufacturing of Recently Approved Oncology... Jan 28 2014
Mercury Pollution in the Upper Valais Collaboration Announced Between the Canton of Valais and Lonza Jan 28 2014
Lonza Delivers Strong Results Following Continuing Success of Transformation Efforts Jan 28 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK